in this release or which are
otherwise made by or on behalf of the Company. Factors which may affect the
Company's results include, but are not limited to, product demand, market
acceptance, impact of competitive products and prices, product development,
completion of an acquisition, commercialization or technological
difficulties, the success or failure of negotiations and trade, legal,
social and economic risks. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements Include but are not limited to, those discussed
in the Company's filings with the Securities and Exchange Commission.
Contact: Derma Sciences, Inc. Allen & Caron Inc
Edward J. Quilty Rudy Barrio (US Investors)
Chairman and CEO r.barrio@allencaron.com
equilty@dermasciences.com
(609) 514-4744 Brian Kennedy (media)
brian@allencaron.com
(212) 691-8087
- FINANCIAL TABLES FOLLOW -
DERMA SCIENCES, INC.
Consolidated Statements of Operations
(Unaudited)
Three Months ended March 31,
2008 2007
Net Sales $11,724,822 $7,965,797
Cost of sales 8,516,164 5,161,369
Gross Profit 3,208,658 2,804,428
Operating expenses
Selling, general and administrative 4,386,866 2,668
'/>"/>
SOURCE Derma Sciences, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
Actavis Receives Approval of Fentanyl Transdermal System in the U.S.2.
Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds3.
AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium4.
Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines5.
Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema6.
Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis7.
Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results8.
Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 20089.
AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skins Natural Antioxidant System10.
Lucid Launches VivaNet(R) Telemedicine Server for Dermatology Applications11.
JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis